IBI3003 Clinical Trials

2 actively recruiting trials

▲ +1 trial since August 2026

Also known as: trispecific antibody

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

Innovent Biologics (Suzhou) Co. Ltd.2

Indications

Cancer2
Relapsed or Refractory Multiple Myeloma1
Multiple Myeloma1

Other2 trials

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Phase 3

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.